These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 36387341)

  • 21. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
    Sato K; Chayama K; Alves K; Toyoda H; Suzuki F; Kato K; Rodrigues L; Zhang X; Setze C; Pilot-Matias T; Burroughs M; Redman R; Kumada H
    Adv Ther; 2017 Jun; 34(6):1449-1465. PubMed ID: 28536999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
    Zheng YX; Ma SJ; Xiong YH; Fan XG
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1477-1487. PubMed ID: 32246857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
    Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.
    Wedemeyer H; Craxí A; Zuckerman E; Dieterich D; Flisiak R; Roberts SK; Pangerl A; Zhang Z; Martinez M; Bao Y; Calleja JL
    J Viral Hepat; 2017 Nov; 24(11):936-943. PubMed ID: 28480525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4.
    Leung DH; Wirth S; Yao BB; Viani RM; Gonzalez-Peralta RP; Jonas MM; Lobritto SJ; Narkewicz MR; Sokal E; Fortuny C; Hsu EK; Del Valle-Segarra A; Zha J; Larsen L; Liu L; Shuster DL; Cohen DE; Rosenthal P
    Hepatol Commun; 2018 Nov; 2(11):1311-1319. PubMed ID: 30411078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy.
    Melendez-Mena D; Mendoza-Torres MA; Sedeño-Monge V; García Y García VH; Rivera-García E; Sánchez-Reza L; Baxin Domínguez MDC; Guzmán-Flores B; Martinez-Laguna Y; Coronel Espinoza JM; Galindo-Santiago I; Flores-Alonso JC; Vallejo-Ruiz V; Cortes-Hernandez P; Reyes-Leyva J; Sosa-Jurado F; Santos-López G
    PeerJ; 2021; 9():e12051. PubMed ID: 34616602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
    El Kassas M; Alboraie M; Omar H; El Latif YA; Algaber MA; El Tahan A; El Halwagy H; Afify S; Elserafy M; Elsaeed K; Doss W
    J Med Virol; 2022 Feb; 94(2):667-674. PubMed ID: 30950069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.
    Poordad F; Castro RE; Asatryan A; Aguilar H; Cacoub P; Dieterich D; Marinho RT; Carvalho A; Siddique A; Hu YB; Charafeddine M; Bondin M; Khan N; Cohen DE; Felizarta F
    J Viral Hepat; 2020 May; 27(5):497-504. PubMed ID: 31954087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
    Crespo J; Calleja JL; Fernández I; Sacristan B; Ruiz-Antorán B; Ampuero J; Hernández-Conde M; García-Samaniego J; Gea F; Buti M; Cabezas J; Lens S; Morillas RM; Salcines JR; Pascasio JM; Turnes J; Sáez-Royuela F; Arenas J; Rincón D; Prieto M; Jorquera F; Sanchez Ruano JJ; Navascués CA; Molina E; Moya AG; Moreno-Planas JM;
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):945-949.e1. PubMed ID: 28238958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.
    Aygen B; Demirtürk N; Yıldız O; Çelen MK; Çelik İ; Barut Ş; Ural O; Batırel A; Mıstık R; Şimşek F; Asan A; Ersöz G; Türker N; Bilgin H; Kınıklı S; Karakeçili F; Zararsız G; Turkish Society Of Clinical Microbiology And Infectious Diseases TSGFVHOT
    Turk J Gastroenterol; 2020 Apr; 31(4):305-317. PubMed ID: 32412901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C: efficacy and safety in real life.
    Flisiak R; Pogorzelska J; Flisiak-Jackiewicz M
    Liver Int; 2017 Jan; 37 Suppl 1():26-32. PubMed ID: 28052633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S
    Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
    Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
    J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.
    Yousif MM; Ahmed H; Elsadek HM; Shendi AM; Gouda TM; Elsayed IA; Gendia MA; Magdy MM; Lbrahim NF; Sadek AMEM; Zaki AM; Shafeik H; Zahran MH
    J Viral Hepat; 2020 Nov; 27(11):1190-1201. PubMed ID: 32564500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.
    Mendizabal M; Haddad L; Gallardo PE; Ferrada A; Soza AA; Adrover R; Aravena E; Roblero JP; Prieto J; Vujacich C; Romero G; Muñoz A; Anders M; Hernández N; Coccozella D; Gruz F; Reggiardo MV; Ruf AE; Varón A; Cartier M; Pérez Ravier R; Ridruejo E; Peralta M; Poncino D; Vorobioff J; Aballay Soteras G; Silva MO
    J Med Virol; 2017 Sep; 89(9):1590-1596. PubMed ID: 28370222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.
    Lawitz E; Gane E; Cohen E; Vierling J; Agarwal K; Hassanein T; Mantry PS; Pockros PJ; Bennett M; Kemmer N; Morelli G; Zha J; Wang D; Shulman NS; Cohen DE; Reddy KR
    Kidney Int Rep; 2019 Feb; 4(2):257-266. PubMed ID: 30775622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real world experience with the all-oral interferon free regimen for the treatment of chronic hepatitis c virus infection in the Lebanese population.
    Saba J; Abou Rached A; Yaghi C; Sharara A; Ammar W
    J Infect Dev Ctries; 2018 Feb; 12(2.1):30S. PubMed ID: 31805005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
    Alqahtani S; Ozaras R; Isakov V; Wyles D; Ferenci P; Feld JJ; Calinas F; Gschwantler M; Gane E; Crawford D; Jacobson IM; Dumas EO; King M; Sulkowski M
    J Viral Hepat; 2017 Apr; 24(4):280-286. PubMed ID: 27935166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.